ECSP034762A - Nuevos compuestos antiinflamatorias de triazolopiridinas - Google Patents

Nuevos compuestos antiinflamatorias de triazolopiridinas

Info

Publication number
ECSP034762A
ECSP034762A EC2003004762A ECSP034762A ECSP034762A EC SP034762 A ECSP034762 A EC SP034762A EC 2003004762 A EC2003004762 A EC 2003004762A EC SP034762 A ECSP034762 A EC SP034762A EC SP034762 A ECSP034762 A EC SP034762A
Authority
EC
Ecuador
Prior art keywords
alkyl
nitrogen
hydrogen
triazolopiridines
group
Prior art date
Application number
EC2003004762A
Other languages
English (en)
Inventor
Mark Anthony Dombroski
Allen Jacob Duplantier
Kim Francis Mcclure
Michael A Letavic
Ellen R Laird
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP034762A publication Critical patent/ECSP034762A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a nuevas triazolopiridinas de fórmula I en al que Het es un heterociclo de 5 miembros opcionalmente sustituido que contiene uno a dos heteroátomos seleccionados de nitrógeno, azufre y oxígeno, debiendo ser nitrógeno al menos uno de dichos heteroátomos. R2 se selecciona del grupo constituido por hidrógeno, alquilo (C1-C6) u otros sustituyentes adecuados; R3 se selecciona del grupo constituido por hidrógeno alquilo (C1-C6) u otros sustituyentes adecuados: s es un número entero de cero a cinco; a intermediarios para su preparación, a composiciones farmacéuticas que los contienen y a su uso medicinal. Los compuestos de la presente invención son potentes inhibidores de las MAP quinasas, preferiblemente de la P38 quinasa. Son útiles en el tratamiento de la inflamación, osteroartritis, artritis reumatoide, cáncer, reperfusión o isquemia en la apoplejía o en el ataque cardíaco, enfermedades autoinmunes y otros trastornos.
EC2003004762A 2001-03-09 2003-09-09 Nuevos compuestos antiinflamatorias de triazolopiridinas ECSP034762A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27484001P 2001-03-09 2001-03-09

Publications (1)

Publication Number Publication Date
ECSP034762A true ECSP034762A (es) 2003-10-28

Family

ID=23049813

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004762A ECSP034762A (es) 2001-03-09 2003-09-09 Nuevos compuestos antiinflamatorias de triazolopiridinas

Country Status (37)

Country Link
US (1) US6696464B2 (es)
EP (1) EP1370559B1 (es)
JP (1) JP4130774B2 (es)
KR (1) KR20030080087A (es)
CN (1) CN1496366A (es)
AP (1) AP2002002463A0 (es)
AR (1) AR036152A1 (es)
AT (1) ATE323701T1 (es)
BG (1) BG108133A (es)
BR (1) BR0207990A (es)
CA (1) CA2440222C (es)
CR (1) CR7013A (es)
CZ (1) CZ20032185A3 (es)
DE (1) DE60210755T2 (es)
DO (1) DOP2002000353A (es)
EA (1) EA200300864A1 (es)
EC (1) ECSP034762A (es)
EE (1) EE200300437A (es)
ES (1) ES2260415T3 (es)
GT (1) GT200200042A (es)
HR (1) HRP20030719A2 (es)
HU (1) HUP0303415A2 (es)
IL (1) IL156567A0 (es)
IS (1) IS6858A (es)
MA (1) MA26991A1 (es)
MX (1) MXPA03008144A (es)
NO (1) NO20033969L (es)
NZ (1) NZ526528A (es)
OA (1) OA12552A (es)
PA (1) PA8541001A1 (es)
PE (1) PE20030010A1 (es)
PL (1) PL363959A1 (es)
SK (1) SK10272003A3 (es)
TN (1) TNSN02022A1 (es)
UY (1) UY27199A1 (es)
WO (1) WO2002072579A1 (es)
ZA (1) ZA200304983B (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372206B1 (en) * 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1854798A3 (en) * 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
GB0124931D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
AU2002364082A1 (en) * 2001-12-19 2003-07-09 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
BRPI0307351B8 (pt) 2002-02-12 2021-05-25 Smithkline Beecham Corp composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
US7012143B2 (en) 2002-08-30 2006-03-14 Dombroski Mark A Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
PA8579601A1 (es) 2002-08-30 2004-05-07 Pfizer Prod Inc Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
US6949652B2 (en) 2002-08-30 2005-09-27 Pfizer, Inc. Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine
US7037923B2 (en) 2002-08-30 2006-05-02 Pfizer, Inc. Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines
EP1537107A2 (en) * 2002-08-30 2005-06-08 Pfizer Products Inc. Novel processes and intermediates for preparing triazolo-pyridines
US7005523B2 (en) 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
US20040092547A1 (en) * 2002-08-30 2004-05-13 Pfizer Inc Alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
JP2006517580A (ja) * 2003-02-14 2006-07-27 ファイザー・プロダクツ・インク 抗炎症化合物としてのトリアゾロピリジン
MXPA05009459A (es) 2003-03-03 2006-05-17 Array Biopharma Inc Inhibidores de p38 y sus metodos de uso.
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
GB0308201D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308186D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308185D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
KR20060120205A (ko) * 2003-12-18 2006-11-24 화이자 프로덕츠 인코포레이티드 ｐ38 ＭＡＰ 키나제 억제제를 사용하여 동물의 급성 염증을치료하는 방법
GB0402143D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
TWI332003B (en) 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
WO2006004702A1 (en) * 2004-06-25 2006-01-12 Amgen Inc. Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases
DE602005010714D1 (de) * 2004-08-12 2008-12-11 Pfizer Der p38-map-kinase
KR100871535B1 (ko) 2004-08-12 2008-12-05 화이자 인코포레이티드 Ｐ38 ｍａｐ 키나아제 억제제로서의트리아졸로피리딘일설판일 유도체
US20090215817A1 (en) * 2004-08-18 2009-08-27 Pfizer Inc Novel Triazolopyridine Compounds for the Treatment of Inflammation
JP2008509987A (ja) * 2004-08-18 2008-04-03 ファルマシア アンド アップジョン カンパニー リミテッド ライアビリティ カンパニー トリアゾロピリジン化合物
US20080051416A1 (en) * 2004-10-05 2008-02-28 Smithkline Beecham Corporation Novel Compounds
US7572807B2 (en) * 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7579360B2 (en) * 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
PE20070341A1 (es) * 2005-07-29 2007-04-13 Wyeth Corp Derivados de pirrol como moduladores del receptor de progesterona
PE20070182A1 (es) 2005-07-29 2007-03-06 Wyeth Corp Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona
PE20070404A1 (es) * 2005-07-29 2007-05-10 Wyeth Corp Compuestos derivados de cianopirrol-sulfonamida como moduladores del receptor de progesterona
AU2007210073B2 (en) 2006-01-31 2011-10-06 Array Biopharma Inc. Kinase inhibitors and methods of use thereof
JP2010500365A (ja) 2006-08-07 2010-01-07 インサイト・コーポレイション キナーゼ阻害剤としてのトリアゾロトリアジン
ES2301380B1 (es) 2006-08-09 2009-06-08 Laboratorios Almirall S.A. Nuevos derivados de 1,7-naftiridina.
MX2009003650A (es) 2006-10-06 2009-04-22 Abbott Lab Nuevos imidazotiazoles e imidazoxazoles.
ES2560435T3 (es) 2006-11-22 2016-02-19 Incyte Holdings Corporation Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa
ES2320955B1 (es) * 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
ES2329639B1 (es) 2007-04-26 2010-09-23 Laboratorios Almirall S.A. Nuevos derivados de 4,8-difenilpoliazanaftaleno.
WO2009005675A1 (en) * 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
MX2010002312A (es) * 2007-08-31 2010-03-18 Merck Serono Sa Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis.
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
MX393622B (es) 2008-05-21 2025-03-24 Incyte Corp Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas.
US8987251B2 (en) 2008-08-19 2015-03-24 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
US8557809B2 (en) 2008-08-19 2013-10-15 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物
US8895550B2 (en) 2008-08-19 2014-11-25 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
PT2464645T (pt) 2009-07-27 2017-10-11 Gilead Sciences Inc Compostos heterocíclicos fusionados como moduladores do canal de iões
EP2322176A1 (en) 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
JP5714030B2 (ja) 2010-02-03 2015-05-07 インサイト コーポレーションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｃ−Ｍｅｔ阻害剤としてのイミダゾ［１，２−ｂ］［１，２，４］トリアジン
WO2012003392A1 (en) 2010-07-02 2012-01-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
WO2012065297A1 (en) * 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
CN103370316B (zh) * 2010-11-16 2015-06-24 南京英派药业有限公司 作为细胞增殖抑制剂的3-芳基-6-芳基-[1,2,4]三唑并[4,3-a]吡啶及其应用
UA111075C2 (uk) 2011-02-25 2016-03-25 Еррей Біофарма Інк. Триазолопіридинові сполуки як інгібітори кінази рім
AU2012253653A1 (en) 2011-05-10 2013-05-02 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (es) 2011-07-01 2018-04-28
BR112015022488A2 (pt) * 2013-03-14 2017-07-18 Genentech Inc triazolopiridinas substituídas e métodos de uso das mesmas
GB201321742D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2015157955A1 (en) 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071144A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION
CN116514801B (zh) * 2022-01-20 2024-11-08 四川大学 2-苯基-[1,2,4]三唑并[1,5-a]吡啶类化合物、其氮氧化物及用途
CN114504636B (zh) * 2022-01-27 2023-09-26 华南理工大学 一种杏仁油烫伤膏及其制备方法与应用
WO2024052684A1 (en) 2022-09-09 2024-03-14 MyricX Pharma Limited Antibody drug conjugate comprising nmt inhibitor and its use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US576499A (en) * 1897-02-02 Gas apparatus
US5716972A (en) * 1993-01-13 1998-02-10 Smithkline Beecham Corporation Pyridyl substituted imidazoles
AU686669B2 (en) 1993-09-17 1998-02-12 Smithkline Beecham Corporation Drug binding protein
IT1269176B (it) * 1994-01-11 1997-03-21 Isagro Srl Eterobicicli ad attivita' fungicida
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
TR199801361T2 (xx) 1996-01-11 1998-10-21 Smithkline Beecham Corporation Yeni ikameli imidazol bile�imleri.
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
EP1082320A4 (en) 1998-05-26 2001-11-21 Smithkline Beecham Corp NEW SUBSTITUTED IMIDAZOLE COMPOUNDS
US6207687B1 (en) * 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
US6350744B1 (en) 1998-11-20 2002-02-26 Merck & Co., Inc. Compounds having cytokine inhibitory activity
ES2188280T3 (es) 1998-12-16 2003-06-16 Aventis Pharma Ltd Acetales heteroaril-ciclicos.
JP2002534385A (ja) 1999-01-08 2002-10-15 スミスクライン・ビーチャム・コーポレイション 新規化合物
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Healthcare Llc .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
CO5170501A1 (es) 1999-04-14 2002-06-27 Novartis Ag AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO

Also Published As

Publication number Publication date
HRP20030719A2 (en) 2005-04-30
BR0207990A (pt) 2004-04-27
UY27199A1 (es) 2002-10-31
PL363959A1 (en) 2004-11-29
ES2260415T3 (es) 2006-11-01
EP1370559A1 (en) 2003-12-17
WO2002072579A1 (en) 2002-09-19
CR7013A (es) 2003-11-25
ZA200304983B (en) 2004-06-29
MA26991A1 (fr) 2004-12-20
JP4130774B2 (ja) 2008-08-06
CZ20032185A3 (en) 2004-06-16
CA2440222A1 (en) 2002-09-19
EA200300864A1 (ru) 2003-12-25
HUP0303415A2 (hu) 2004-01-28
AP2002002463A0 (en) 2002-06-30
MXPA03008144A (es) 2003-12-12
US6696464B2 (en) 2004-02-24
KR20030080087A (ko) 2003-10-10
TNSN02022A1 (fr) 2005-12-23
DE60210755D1 (de) 2006-05-24
GT200200042A (es) 2003-02-11
SK10272003A3 (sk) 2004-07-07
US20030096838A1 (en) 2003-05-22
IL156567A0 (en) 2004-01-04
AR036152A1 (es) 2004-08-18
DE60210755T2 (de) 2006-11-16
NZ526528A (en) 2005-02-25
JP2004522799A (ja) 2004-07-29
CN1496366A (zh) 2004-05-12
EP1370559B1 (en) 2006-04-19
EE200300437A (et) 2004-02-16
IS6858A (is) 2003-06-23
DOP2002000353A (es) 2002-10-15
ATE323701T1 (de) 2006-05-15
OA12552A (en) 2006-06-06
NO20033969L (no) 2003-10-13
PA8541001A1 (es) 2003-05-14
NO20033969D0 (no) 2003-09-08
PE20030010A1 (es) 2003-01-29
CA2440222C (en) 2008-11-18
BG108133A (bg) 2004-09-30

Similar Documents

Publication Publication Date Title
DOP2002000353A (es) Nuevos compuestos antiinflamatorios de triazolopiridinas
DOP2002000349A (es) Nuevos compuestos antiinflamatorios de bencimidazol
CA2379903A1 (en) Novel benzotriazoles anti-inflammatory compounds
MXPA05008568A (es) Nuevos compuestos anti-inflamatorios triazolo-piridinas.
ES2204539T3 (es) Derivados de piridina y pirimidina y su uso como inhibidores de enfermedades mediadas por citoquinas.
GT200000002A (es) Ureas difenilicias x - carboxyaril sustituidas como inhibidores raf kinase.
AP2000001964A0 (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation.
BG106527A (en) Pharmaceutically active sulfonamide derivatives
RU94031155A (ru) Амидин - производные, способ их получения, их использование в качестве ингибиторов no - синтазы, фармсостав, способ лечения
AR048642A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento
AR029383A1 (es) Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes
ES2134926T3 (es) Derivados vinileno-azaindolicos y su procedimiento de preparacion.
AR023659A1 (es) Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos
NO20024154L (no) Pyrimidinforbindelser
FI884879A0 (fi) Terapeutiskt anvaendbara heterocykliska foereningar.
MA23433A1 (fr) Nouvelles compositions leurs procedes de preparation et leur emploi
CO5261551A1 (es) Nuevos derivados de biarileter utiles como inhibidores de la recaptacion de monoaminas
YU64092A (sh) Fluoralkoksibenzamino derivati heterocikličnih jedinjenja koja sadrže azot
MX9300031A (es) Derivados de piperazina, procedimiento para su preparacion y composicion farmaucetica que los contiene.
ATE425142T1 (de) Inhibitoren von c-jun n-terminal kinasen (jnk)
TW200420562A (en) Di and trifluoro-triazolo-pyridines anti-inflammatory compounds
ES2920888T3 (es) Derivado de sulfonamida y método de preparación y uso del mismo
SE8307133D0 (sv) Carboxamido-derivatives of 5h-1,3,4-thiadiazolo(3,2-a)pyrimidines and process for their preparation
BR0313961A (pt) Processos e intermediários para preparar triazolo-piridinas
BRPI0417928A (pt) composto, composição farmacêutica, métodos para o tratamento ou a prevenção de uma condição mediada pelo receptor de bradicinina b1, e de dor em um mamìfero, e, uso de um composto